BD to acquire Bard in $24 billion medical tech deal

“We will be able to partner [with providers] on fundamental treatment processes in a way that no one else can”, Becton Dickinson CEO Vincent Forlenza told Reuters.

A number of key analysts, polled by FactSet, shared their views about the current stock momentum.

The market experts are predicting a 73.91% rally, based on the high target price ($4) for Northern Oil and Gas, Inc. shares that is likely to be hit in the 52 weeks. They now have a Dollars 175 price target on the stock. Looking at this figure it suggests that the shares of Becton, Dickinson and Company (BDX) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that Becton, Dickinson and Company (BDX) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target. Recently, analysts have updated the overall rating to 2.3. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Citigroup also Downgrade the company to Sell on 23-Sep-16, 2016. They now have a Dollars 165 price target on the stock. Becton Dickinson had 19 analyst reports since August 7, 2015 according to SRatingsIntel.

3/29/2017-Jefferies Group LLC Reiterated Rating of Buy. They now have a Dollars 192 price target on the stock. They now have a Dollars 169 price target on the stock. The rating was upgraded by Deutsche Bank on Thursday, February 11 to “Buy”.

02/04/2016 – Becton, Dickinson and Company had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a United States dollars 170 price target on the stock. They now have a Dollars 171 price target on the stock.

Becton, Dickinson will pay $317 a share for Bard in cash and shares. Becton, Dickinson and Co.is showing a gain of 7.8% looking at the year to date performance. Additionally, BDX had a day price range of $175.66 to $180.26. The stock’s market capitalization is 37.68B. The stock’s 52-week range is $157.60 – $186.40.

– By combining Bard’s strong leadership position and innovation pipeline in fast-growing vascular access segments – PICCs (peripherally inserted central catheters), midlines and drug delivery ports – with BD’s leadership and innovation in IV drug preparation, dispensing, delivery and administration, the new company will be better positioned to provide end-to-end medication management solutions across the care continuum. The Company operates through two segments: BD Medical and BD Life Sciences. Becton, Dickinson and Company (BDX) is a part of Healthcare sector and belongs to Medical Instruments & Supplies industry. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. He will oversee all of BD’s operating segments including a new Interventional segment, which will include the Bard businesses when the deal closes.